Provided by Tiger Trade Technology Pte. Ltd.

MiNK Therapeutics, Inc.

12.20
+0.58004.99%
Post-market: 12.200.00000.00%19:30 EDT
Volume:11.78K
Turnover:139.64K
Market Cap:62.26M
PE:-5.09
High:12.20
Open:11.64
Low:11.22
Close:11.62
52wk High:16.98
52wk Low:8.48
Shares:5.10M
Float Shares:2.07M
Volume Ratio:1.15
T/O Rate:0.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3970
EPS(LYR):-2.9257
ROE:-1238.98%
ROA:-129.34%
PB:-4.44
PE(LYR):-4.17

Loading ...

MiNK Therapeutics doses first patient in agenT-797 trial

TIPRANKS
·
May 28

BUZZ-MiNK Therapeutics jumps after first patient dosed in lung injury study

Reuters
·
May 28

Mink Therapeutics doses first patient in Phase 2 agenT-797 acute lung injury trial

Reuters
·
May 28

Mink Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of Agent-797 in Acute Lung Injury and Critical Illness

THOMSON REUTERS
·
May 28

MiNK Therapeutics reports new data on agenT-797 at ATS 2026

TIPRANKS
·
May 20

Mink Therapeutics starts Phase 2 trial of agenT-797 in severe acute lung injury

Reuters
·
May 20

MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications

GlobeNewswire
·
May 20

MiNK Therapeutics Price Target Maintained With a $35.00/Share by HC Wainwright & Co.

Dow Jones
·
May 18

Analysts Are Bullish on These Healthcare Stocks: Biofrontera (BFRI), MiNK Therapeutics (INKT)

TIPRANKS
·
May 18

Mink Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 16

MiNK Therapeutics Q1 EPS $(0.57) Beats $(0.78) Estimate

Benzinga Earnings
·
May 15

MiNK Therapeutics Q1 FY26 net loss narrows to $2.74 million

Reuters
·
May 15

BRIEF-MiNK Therapeutics Q1 EPS USD -0.57

Reuters
·
May 15

Mink Therapeutics Q1 EPS USD -0.57

THOMSON REUTERS
·
May 15

Press Release: MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation

Dow Jones
·
May 15

MiNK Therapeutics initiates agenT-797 clinical trial

TIPRANKS
·
May 15

Mink Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of Agent-797 in Acute Lung Injury and Critical Illness

THOMSON REUTERS
·
May 14

Mink Therapeutics Inc: Preliminary Data Expected in Second Half of 2026

THOMSON REUTERS
·
May 14

MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness

GlobeNewswire
·
May 14

Mink Therapeutics Inc expected to post a loss of 77 cents a share - Earnings Preview

Reuters
·
May 13